(68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment: Prostate

G. Habl; K. Sauter; K. Schiller; S. Dewes; T. Maurer; M. Eiber; S. E. Combs

doi:10.1002/pros.23347

(68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment

Standard

(68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment : Prostate. / Habl, G.; Sauter, K.; Schiller, K.; Dewes, S.; Maurer, T.; Eiber, M.; Combs, S. E.

In: PROSTATE, Vol. 77, No. 8, 2017, p. 920-927.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research

Harvard

Habl, G, Sauter, K, Schiller, K, Dewes, S, Maurer, T, Eiber, M & Combs, SE 2017, '(68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment: Prostate', PROSTATE, vol. 77, no. 8, pp. 920-927. https://doi.org/10.1002/pros.23347

APA

Habl, G., Sauter, K., Schiller, K., Dewes, S., Maurer, T., Eiber, M., & Combs, S. E. (2017). (68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment: Prostate. PROSTATE, 77(8), 920-927. https://doi.org/10.1002/pros.23347

Vancouver

Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M et al. (68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment: Prostate. PROSTATE. 2017;77(8):920-927. https://doi.org/10.1002/pros.23347

Bibtex

@article{98a8e97c8fe947ccb786b6dd2566c621,

title = "(68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment: Prostate",

abstract = "BACKGROUND: (68) Ga-PSMA-PET imaging is a novel promising diagnostic tool to locate early biochemical failure after radical prostatectomy (RP) in prostate cancer (PC) patients. Exact knowledge of the relapse location may result in changes of the therapy concept aside from changes to the TNM stage. To gain data for this approach, we evaluated PC patients receiving (68) Ga-PSMA-PET imaging before salvage radiotherapy (RT). METHODS AND MATERIALS: In this study, 100 patients with biochemical failure after RP+/- prior RT who underwent (68) Ga-PSMA PET/CT or PET/MRI were evaluated undergoing salvage RT in our department. We analyzed TNM staging changes due to (68) Ga-PSMA-PET imaging and its influence on RT planning and treatment. RESULTS: Uptake indicative for tumor recurrence in (68) Ga-PSMA-PET was found in 76% of the patients with biochemical recurrent PC. Median PSA level was 1.0 ng/mL (range 0.12-14.7 ng/mL). Of these, 80% showed no morphological correlate in the corresponding CT or MRI. A 43% of all patients experienced a change in TNM stage due to (68) Ga-PSMA-PET imaging. Patients had changes from Tx to rcT+ (28%), 12% from pN0 to rcN1, 1% from pN0/cM0 to rcM1a, and 8% from cM0 to rcM1b. Due to the additional knowledge of (68) Ga-PSMA-PET imaging, initial planned RT planning was adapted in 59% of all cases. An additional simultaneous integrated boost (SIB) to the prostate bed or lymph nodes was given to 32% and 63%, respectively. Ten patients received stereotactic body RT (SBRT) to single bone metastases. CONCLUSION: (68) Ga-PSMA-PET imaging showed a high clinical impact on staging and RT management in patients with biochemically recurrent PC, even at low serum PSA levels. With 43% changes in staging and 59% in radiotherapy planning (68) Ga-PSMA-PET could lead to an indispensable tool in guiding radiation treatment in recurrent PC.",

keywords = "Aged Biochemical Phenomena *Bone Neoplasms/chemistry/pathology/secondary Gallium Radioisotopes/*pharmacology Humans Magnetic Resonance Imaging/*methods Male Middle Aged Multimodal Imaging/methods Neoplasm Staging Patient Care Planning Positron Emission Tomography Computed Tomography/methods Prostatectomy/*adverse effects/methods *Prostatic Neoplasms/chemistry/diagnosis/pathology Radiopharmaceuticals/pharmacology Radiotherapy, Adjuvant/methods Recurrence Reproducibility of Results Psma individualized radiotherapy prostate cancer restaging salvage radiotherapy",

author = "G. Habl and K. Sauter and K. Schiller and S. Dewes and T. Maurer and M. Eiber and Combs, {S. E.}",

note = "1097-0045 Habl, Gregor ORCID: http://orcid.org/0000-0002-5719-7567 Sauter, Katharina Schiller, Kilian Dewes, Sabrina Maurer, Tobias Eiber, Matthias Combs, Stephanie E Journal Article United States Prostate. 2017 Jun;77(8):920-927. doi: 10.1002/pros.23347. Epub 2017 Mar 20.",

year = "2017",

doi = "10.1002/pros.23347",

language = "English",

volume = "77",

pages = "920--927",

journal = "PROSTATE",

issn = "0270-4137",

publisher = "Wiley-Liss Inc.",

number = "8",

}

RIS

TY - JOUR

T1 - (68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment

T2 - Prostate

AU - Habl, G.

AU - Sauter, K.

AU - Schiller, K.

AU - Dewes, S.

AU - Maurer, T.

AU - Eiber, M.

AU - Combs, S. E.

N1 - 1097-0045 Habl, Gregor ORCID: http://orcid.org/0000-0002-5719-7567 Sauter, Katharina Schiller, Kilian Dewes, Sabrina Maurer, Tobias Eiber, Matthias Combs, Stephanie E Journal Article United States Prostate. 2017 Jun;77(8):920-927. doi: 10.1002/pros.23347. Epub 2017 Mar 20.

PY - 2017

Y1 - 2017

N2 - BACKGROUND: (68) Ga-PSMA-PET imaging is a novel promising diagnostic tool to locate early biochemical failure after radical prostatectomy (RP) in prostate cancer (PC) patients. Exact knowledge of the relapse location may result in changes of the therapy concept aside from changes to the TNM stage. To gain data for this approach, we evaluated PC patients receiving (68) Ga-PSMA-PET imaging before salvage radiotherapy (RT). METHODS AND MATERIALS: In this study, 100 patients with biochemical failure after RP+/- prior RT who underwent (68) Ga-PSMA PET/CT or PET/MRI were evaluated undergoing salvage RT in our department. We analyzed TNM staging changes due to (68) Ga-PSMA-PET imaging and its influence on RT planning and treatment. RESULTS: Uptake indicative for tumor recurrence in (68) Ga-PSMA-PET was found in 76% of the patients with biochemical recurrent PC. Median PSA level was 1.0 ng/mL (range 0.12-14.7 ng/mL). Of these, 80% showed no morphological correlate in the corresponding CT or MRI. A 43% of all patients experienced a change in TNM stage due to (68) Ga-PSMA-PET imaging. Patients had changes from Tx to rcT+ (28%), 12% from pN0 to rcN1, 1% from pN0/cM0 to rcM1a, and 8% from cM0 to rcM1b. Due to the additional knowledge of (68) Ga-PSMA-PET imaging, initial planned RT planning was adapted in 59% of all cases. An additional simultaneous integrated boost (SIB) to the prostate bed or lymph nodes was given to 32% and 63%, respectively. Ten patients received stereotactic body RT (SBRT) to single bone metastases. CONCLUSION: (68) Ga-PSMA-PET imaging showed a high clinical impact on staging and RT management in patients with biochemically recurrent PC, even at low serum PSA levels. With 43% changes in staging and 59% in radiotherapy planning (68) Ga-PSMA-PET could lead to an indispensable tool in guiding radiation treatment in recurrent PC.

AB - BACKGROUND: (68) Ga-PSMA-PET imaging is a novel promising diagnostic tool to locate early biochemical failure after radical prostatectomy (RP) in prostate cancer (PC) patients. Exact knowledge of the relapse location may result in changes of the therapy concept aside from changes to the TNM stage. To gain data for this approach, we evaluated PC patients receiving (68) Ga-PSMA-PET imaging before salvage radiotherapy (RT). METHODS AND MATERIALS: In this study, 100 patients with biochemical failure after RP+/- prior RT who underwent (68) Ga-PSMA PET/CT or PET/MRI were evaluated undergoing salvage RT in our department. We analyzed TNM staging changes due to (68) Ga-PSMA-PET imaging and its influence on RT planning and treatment. RESULTS: Uptake indicative for tumor recurrence in (68) Ga-PSMA-PET was found in 76% of the patients with biochemical recurrent PC. Median PSA level was 1.0 ng/mL (range 0.12-14.7 ng/mL). Of these, 80% showed no morphological correlate in the corresponding CT or MRI. A 43% of all patients experienced a change in TNM stage due to (68) Ga-PSMA-PET imaging. Patients had changes from Tx to rcT+ (28%), 12% from pN0 to rcN1, 1% from pN0/cM0 to rcM1a, and 8% from cM0 to rcM1b. Due to the additional knowledge of (68) Ga-PSMA-PET imaging, initial planned RT planning was adapted in 59% of all cases. An additional simultaneous integrated boost (SIB) to the prostate bed or lymph nodes was given to 32% and 63%, respectively. Ten patients received stereotactic body RT (SBRT) to single bone metastases. CONCLUSION: (68) Ga-PSMA-PET imaging showed a high clinical impact on staging and RT management in patients with biochemically recurrent PC, even at low serum PSA levels. With 43% changes in staging and 59% in radiotherapy planning (68) Ga-PSMA-PET could lead to an indispensable tool in guiding radiation treatment in recurrent PC.

KW - Aged Biochemical Phenomena Bone Neoplasms/chemistry/pathology/secondary Gallium Radioisotopes/pharmacology Humans Magnetic Resonance Imaging/methods Male Middle Aged Multimodal Imaging/methods Neoplasm Staging Patient Care Planning Positron Emission Tomog

U2 - 10.1002/pros.23347

DO - 10.1002/pros.23347

M3 - SCORING: Journal article

VL - 77

SP - 920

EP - 927

JO - PROSTATE

JF - PROSTATE

SN - 0270-4137

IS - 8

ER -